Subscribe to RSS
DOI: 10.4103/ijmpo.ijmpo_196_20
The Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma using Radiotherapy
Financial support and sponsorship Nil.
Introduction
Gastric mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) is the second-most common subtype of non-Hodgkin's lymphoma, the first being diffuse large B-cell lymphoma (DLBCL).[1] The most common causative organism for gastric MALT lymphoma is Helicobacter pylori. 80% of Stage I and 45%–56% of Stage II patients achieve remission after H. pylori eradication.[2],[3],[4] The treatment options for refractory MALT lymphoma include chemotherapy, radiotherapy, surgery, and immunotherapy. Only a few studies have reported the efficacy and the safety of radiotherapy in the treatment of gastric MALT lymphoma.[5] We report a patient with refractory gastric MALT lymphoma who was treated effectively and safely with advanced radiation technique. The patient is on follow-up with a disease-free survival (DFS) of 12 months duration.
Publication History
Received: 26 April 2020
Accepted: 17 July 2020
Article published online:
17 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: Pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 2005; 89: 313-44, viii
- 2 Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M. et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: A multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-13
- 3 Ahmad A, Govil Y, Frank BB. Gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol 2003; 98: 975-86
- 4 Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E. et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-10
- 5 Park HC, Park W, Hahn JS, Kim CB, Lee YC, Noh JK. et al. Low grade MALT lymphoma of the stomach: Treatment outcome with radiotherapy alone. Yonsei Med J 2002; 43: 601-6
- 6 Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F. et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-58
- 7 Burgers JM, Taal BG, van Heerde P, Somers R, den Hartog Jager FC, Hart AA. Treatment results of primary stage I and II non-Hodgkin's lymphoma of the stomach. Radiother Oncol 1988; 11: 319-26
- 8 Isaacson PG. Gastric MALT lymphoma: From concept to cure. Ann Oncol 1999; 10: 637-45
- 9 Tomita N, Kodaira T, Tachibana H, Nakamura T, Mizoguchi N, Takada A. Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol 2009; 90: 231-5
- 10 Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD. et al. Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Int J Radiat Oncol Biol Phys 2019; 104: 447-55
- 11 Nam TK, Ahn JS, Choi YD, Jeong JU, Kim YH, Yoon MS. et al. The role of radiotherapy in the treatment of gastric mucosa-associated lymphoid tissue lymphoma. Cancer Res Treat 2014; 46: 33-40